KRAS and lung carcinoma: In order to overcome these challenges, identification and characterization of new druggable targets in the KRAS-induced signalling pathways that promote important malignant features is urgently warranted for the development of novel and more effective therapeutic strategies for lung cancer, as well as other RAS-driven malignancies.